Sugi Predict

Sugi Predict / Targets / GSK3A

GSK3A

Glycogen synthase kinase-3 alpha · P49840 · GSK3A on Sugi Atlas →

192,469 patent compounds predicted against GSK3A, 124,863 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Aloisine Aloisine (SCHEMBL79714) 1.00 19/20
Aloisine A Aloisine A (SCHEMBL80147) 1.00 19/20
SCHEMBL26286 SCHEMBL26286 0.50 8/20
SCHEMBL79670 SCHEMBL79670 0.53 6/20
SCHEMBL61934 SCHEMBL61934 0.39 6/20
SCHEMBL114195 SCHEMBL114195 0.46 5/20
SCHEMBL69748 SCHEMBL69748 0.45 5/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 4/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 4/20
SCHEMBL77739 SCHEMBL77739 0.59 4/20
SCHEMBL40679 SCHEMBL40679 0.56 4/20
SCHEMBL6090 SCHEMBL6090 0.53 4/20
SCHEMBL76982 SCHEMBL76982 0.51 4/20
SCHEMBL80967 SCHEMBL80967 0.51 4/20
SCHEMBL30710 SCHEMBL30710 0.46 4/20
SCHEMBL44144 SCHEMBL44144 0.45 4/20
SCHEMBL34594 SCHEMBL34594 0.43 4/20
Pterine Pterine (SCHEMBL64321) 0.34 4/20
Apigenin Apigenin (SCHEMBL19428) 1.00 3/20
Luteolin Luteolin (SCHEMBL20426) 1.00 3/20

Clinical trials — most relevant to GSK3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium for Prevention of Cognitive Declining in Mood Illnesses PHASE4NOT_YET_RECRUITING
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy PHASE2COMPLETED
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis PHASE2COMPLETED
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) PHASE2COMPLETED
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria PHASE2NOT_YET_RECRUITING
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults PHASE2COMPLETED
A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis PHASE2COMPLETED
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects PHASE2COMPLETED
A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer PHASE2COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA) PHASE1COMPLETED
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers PHASE1COMPLETED
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect PHASE1COMPLETED
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects PHASE1COMPLETED
GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers PHASE1COMPLETED
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects PHASE1COMPLETED
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects PHASE1COMPLETED
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma PHASE1COMPLETED
Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 PHASE1COMPLETED
A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects PHASE1COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants PHASE1COMPLETED
GSK372475 PK Study in Healthy Volunteers PHASE1COMPLETED
First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects PHASE1COMPLETED
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults PHASE1COMPLETED
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 PHASE1COMPLETED
Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment nanCOMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GSK3A binder may also engage these)

ProteinNameSimilarity
Q2NL51 — 1.000 Q2NL51 →
P18265 — 1.000 P18265 →
P18266 — 0.996 P18266 →
GSK3B Glycogen synthase kinase-3 beta 0.996 landscape →
Q5YJC2 — 0.995 Q5YJC2 →
P51138 — 0.995 P51138 →
Q9WV60 — 0.995 Q9WV60 →
Q8VZD5 — 0.994 Q8VZD5 →
P18431 — 0.993 P18431 →
P43288 — 0.992 P43288 →
P43289 — 0.992 P43289 →
Q96287 — 0.991 Q96287 →
O04160 — 0.991 O04160 →
Q40518 — 0.991 Q40518 →
Q91757 — 0.991 Q91757 →
O23145 — 0.991 O23145 →
Q39010 — 0.990 Q39010 →
Q501Q9 — 0.990 Q501Q9 →
Q9LWN0 — 0.990 Q9LWN0 →
Q9U2Q9 — 0.989 Q9U2Q9 →
P83101 — 0.989 P83101 →
Q39012 — 0.989 Q39012 →
Q63553 — 0.988 Q63553 →
Q9FVS6 — 0.988 Q9FVS6 →
Q9Z188 — 0.988 Q9Z188 →
SNRK SNF-related serine/threonine-protein kinase 0.988 landscape →
Q39019 — 0.988 Q39019 →
Q60EZ2 — 0.988 Q60EZ2 →
Q4V8A3 — 0.988 Q4V8A3 →
P51137 — 0.987 P51137 →